Anti-CGRP monoclonal antibodies in chronic migraine with medication overuse: real-life effectiveness and predictors of response at 6 months

被引：0
|
作者：
Edoardo Caronna
Victor José Gallardo
Alicia Alpuente
Marta Torres-Ferrus
Patricia Pozo-Rosich
机构：
[1] Universitat Autònoma de Barcelona,Neurology Department, Hospital Universitari Vall d’Hebron, Department of Medicine
[2] Universitat Autònoma de Barcelona,Headache and Neurological Pain Research Group, Vall d’Hebron Research Institute, Department of Medicine
来源：
The Journal of Headache and Pain | 2021年 / 22卷
关键词：
Migraine; Medication overuse; CGRP; Monoclonal antibodies; Erenumab; Galcanezumab;
D O I：
暂无
中图分类号：
学科分类号：
摘要：
引用
收藏
相关论文
共 50 条
  • [1] Anti-CGRP monoclonal antibodies in chronic migraine with medication overuse: real-life effectiveness and predictors of response at 6 months
    Caronna, Edoardo
    Jose Gallardo, Victor
    Alpuente, Alicia
    Torres-Ferrus, Marta
    Pozo-Rosich, Patricia
    JOURNAL OF HEADACHE AND PAIN, 2021, 22 (01):
  • [2] Medication Overuse Headache, Chronic Migraine and Monoclonal Antibodies Anti-CGRP: A Real-World Study
    Krymchantowski, Abouch
    Jevoux, Carla
    Krymchantowski, Ana Gabriela
    Silva-Neto, Raimundo Pereira
    CLINICAL NEUROPHARMACOLOGY, 2023, 46 (05) : 181 - 185
  • [3] Long-term effectiveness of monoclonal anti-CGRP antibodies in patients with migraine in real life
    Perez Prol, C.
    Espinoza Vinces, C.
    Villino Rodriguez, R.
    Atorrasagasti Villar, A.
    Gimeno Rodriguez, M.
    Benitez Martinez, B.
    Beistegui Sarobe, M.
    Sanchez del Rio, M.
    Irimia Sieira, P.
    JOURNAL OF HEADACHE AND PAIN, 2024, 25
  • [4] Late Response to Anti-CGRP Monoclonal Antibodies in Migraine
    Barbanti, Piero
    Aurilia, Cinzia
    Egeo, Gabriella
    Torelli, Paola
    Proietti, Stefania
    Cevoli, Sabina
    Bonassi, Stefano
    NEUROLOGY, 2023, 101 (11) : 482 - 488
  • [5] Effectiveness of anti-CGRP monoclonal antibodies on central symptoms of migraine
    Iannone, Luigi Francesco
    De Cesaris, Francesco
    Ferrari, Anita
    Benemei, Silvia
    Fattori, Davide
    Chiarugi, Alberto
    CEPHALALGIA, 2022, 42 (13) : 1323 - 1330
  • [6] Anti-CGRP monoclonal antibodies in resistant migraine: preliminary real-world effectiveness and clinical predictors of response at two years
    Pons-Fuster, E.
    Lozano-Caballero, O.
    Martin-Balbuena, S.
    Lucas-Rodenas, C.
    Mancebo-Gonzalez, A.
    De Gorostiza-Frias, I.
    Gonzalez-Ponce, C. M.
    INTERNATIONAL JOURNAL OF CLINICAL PHARMACY, 2024, : 1317 - 1326
  • [7] The Arrival of Anti-CGRP Monoclonal Antibodies in Migraine
    Fred Cohen
    Hsiangkuo Yuan
    E. M. G. DePoy
    Stephen D. Silberstein
    Neurotherapeutics, 2022, 19 : 922 - 930
  • [8] Patterns of response to anti-CGRP monoclonal antibodies after 6-months of treatment in resistant migraine patients
    Torres-Ferrus, M.
    Alpuente, A.
    Gine-Cipres, E.
    Caronna, E.
    Gallardo Lopez, V.
    Pozo-Rosich, P.
    JOURNAL OF HEADACHE AND PAIN, 2021, 22 (SUPPL 2):
  • [9] Patterns of response to anti-CGRP monoclonal antibodies after 6-months of treatment in resistant migraine patients
    Torres-Ferrus, M.
    Alpuente, A.
    Gine-Cipres, E.
    Caronna, E.
    Gallardo Lopez, V.
    Pozo-Rosich, P.
    CEPHALALGIA, 2021, 41 (1_SUPPL) : 264 - 265
  • [10] The Arrival of Anti-CGRP Monoclonal Antibodies in Migraine
    Cohen, Fred
    Yuan, Hsiangkuo
    DePoy, E. M. G.
    Silberstein, Stephen D.
    NEUROTHERAPEUTICS, 2022, 19 (03) : 922 - 930
12345